Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 151

Sort by

Sort Order Select

Journal Articles

The location of the t(4;14) translocation breakpoint within the NSD2 gene identifies a subset of patients with high-risk NDMM

Nicholas Stong, María Ortiz-Estévez, Fadi Towfic, Mehmet Samur, Amit Agarwal, Jill Corre, Erin Flynt, Nikhil Munshi, Hervé Avet-Loiseau, Anjan Thakurta

Blood (2023) 141 (13): 1574–1583.

https://doi.org/10.1182/blood.2022016212

Published: 2023

Includes: Supplemental data

Journal Articles

Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed/refractory myeloma

Naser Ansari-Pour, Mehmet Samur, Erin Flynt, Sarah Gooding, Fadi Towfic, Nicholas Stong, Maria Ortiz Estevez, Konstantinos Mavrommatis, Brian Walker, Gareth Morgan, Nikhil Munshi, Herve Avet-Loiseau, Anjan Thakurta

Blood (2023) 141 (6): 620–633.

https://doi.org/10.1182/blood.2022017010

Published: 2023

Includes: Supplemental data

Journal Articles

Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA

Blood (2022) 139 (6): 835–844.

https://doi.org/10.1182/blood.2021011101

Published: 2022

Includes: Supplemental data

Journal Articles

Variable BCL2/BCL2L1 ratio in multiple myeloma with t(11;14)

Alice Cleynen, Mehmet Samur, Aurore Perrot, Laure Buisson, Sabrina Maheo, Mariateresa Fulciniti, Michel Attal, Nikhil Munshi, Hervé Avet-Loiseau, Jill Corre

Blood (2018) 132 (26): 2778–2780.

https://doi.org/10.1182/blood-2018-09-876433

Published: 2018

Journal Articles

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

Blood (2018) 132 (23): 2456–2464.

https://doi.org/10.1182/blood-2018-06-858613

Published: 2018

Includes: Supplemental data

Journal Articles

Preclinical Validation Studies Support Causal Machine Learning Based Identification of Novel Drug Targets for High-Risk Multiple Myeloma

Arnold Bolomsky, Fred Gruber, PhD, Kathrin Stangelberger, MSc, Leon Furchtgott, PhD, Dominik Arnold, Puja Raut, Diane Wuest, PhD, Karl Runge, Iya Khalil, Niklas Zojer, MD, Nikhil Munshi, MD, Boris Hayete, PhD, Heinz Ludwig, MD

Blood (2018) 132 (Supplement 1): 3210.

https://doi.org/10.1182/blood-2018-99-117886

Published: 2018

Journal Articles

APRIL Is Significantly Elevated at All Stages of Multiple Myeloma (MM) and Interferes with Anti-Bcma Monoclonal Antibody-Mediated Cytolysis, Supporting the Clinical Evaluation of Bion-1301 As a Novel Therapeutic Approach in MM

Yu-Tzu Tai, PhD, John Dulos, PhD, Lars Guelen, Liang Lin, PhD, Lijie Xing, MD, Shih-Feng Cho, MD PhD, Kenneth Wen, BS, Tengteng Yu, MD, Phillip A Hsieh, Peter van Zandvoort, Bsc, Guido van de Wiel, Jos van de Crommert, Bsc, Bonny Lejeune, Hamid Namini, Hans Eenennaam, PhD, Andrea van Elsas, PhD, Paul Richardson, Nikhil Munshi, MD, Kenneth C. Anderson, MD

Blood (2018) 132 (Supplement 1): 3209.

https://doi.org/10.1182/blood-2018-99-117296

Published: 2018

Journal Articles

A High-Risk Multiple Myeloma Group Identified By Integrative Multi-Omics Segmentation of Newly Diagnosed Patients

Maria Ortiz, Fadi Towfic, PhD, Mehmet Kemal Samur, PhD, Erin Flynt, In Sock Jang, PhD, Kai Wang, PhD, Cody Ashby, PhD, Brian A Walker, PhD, Matthew Trotter, PhD, Gareth Morgan, MD, Nikhil Munshi, MD, Anjan Thakurta, PhD

Blood (2018) 132 (Supplement 1): 3165.

https://doi.org/10.1182/blood-2018-99-117114

Published: 2018

Journal Articles

Deciphering the Chronology of Copy Number Alterations in Multiple Myeloma (MM): What Comes First?

Anil Aktas Samur, PhD, Mehmet Kemal Samur, PhD, Stephane Minvielle, PhD, Florence Magrangeas, PhD, Masood A. Shammas, PhD, Mariateresa Fulciniti, PhD, Michel Attal, MD PhD, Philippe Moreau, Kenneth Anderson, MD, Giovanni Parmigiani, Hervé Avet-Loiseau, MD PhD, Nikhil Munshi, MD

Blood (2018) 132 (Supplement 1): 3171.

https://doi.org/10.1182/blood-2018-99-120101

Published: 2018

Journal Articles

Dysregulated Translational Control Is a Central Feature of MM Mediated By 14-3-3ε Interactome Promoting Multiple Myeloma Cell Growth and Viability

Blood (2018) 132 (Supplement 1): 3176.

https://doi.org/10.1182/blood-2018-99-118994

Published: 2018

Journal Articles

Activation of the Non-Canonical Estrogen Receptor Gper As a Novel Therapeutic Strategy Against WaldenstrÃ¶m Macroglobulinemia

Nicola Amodio, PhD, Giada Juli, PhD, Eugenio Morelli, MD, Maria Angelica Stamato, PhD, Maria Eugenia Gallo Cantafio, PhD, Cinzia Federico, PhD, Katia Todoerti, PhD, Emanuela Altomare, Katia Grillone, PhD, Marco Rossi, MD, Michele Cea, MD, Antonino Neri, MD, Mariateresa Fulciniti, PhD, Nikhil Munshi, MD, Pierosandro Tagliaferri, Pierfrancesco Tassone, MD

Blood (2018) 132 (Supplement 1): 1585.

https://doi.org/10.1182/blood-2018-99-110928

Published: 2018

Journal Articles

Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Chia-jen Liu, MD, Irene M. Ghobrial, MD, Mark Bustoros, MD, Kaitlen Reyes, NP, Kalvis Hornburg, BA, Ashraf Z. Badros, MD, James J. Vredenburgh, MD, Adam Boruchov, MD, Jeffrey V Matous, MD, Aaron Caola, BS, Bradley Rivotto, BS, Alexandra Savell, BS, Patrick Henrick, BS, Claudia E. Paba-Prada, MD, Robert L. Schlossman, MD, Jacob Laubach, MD, Jacalyn Rosenblatt, MD, Andrew J Yee, MD, Omar Nadeem, MD, Rodrigo O. Maegawa, MD, Andrzej Jakubowiak, MD PhD, Saad Z. Usmani, MD, Manisha Bhutani, MD, Joseph Cappuccio, BS, Brianna Berrios, BS, Kimberly Noonan, NP, Oksana Zavidij, PhD, Tarek H Mouhieddine, MD, Cody J Boehner, Carl-Jannes Neuse, Karma Ziad Salem, MD, Mairead Reidy, PhD, Jihye Park, PhD, Michael Agius, PhD, Mahshid Rahmat, PhD, Salomon Manier, MD PhD, Divaya Bhutani, MD, Jeffrey A Zonder, MD, Nikhil Munshi, MD, Daniel Auclair, PhD, Kenneth Anderson, MD, Paul Richardson

Blood (2018) 132 (Supplement 1): 154.

https://doi.org/10.1182/blood-2018-154

Published: 2018

Journal Articles

APOBEC3B Is Induced By Activation of DNA Repair Pathway and Modulates the Survival and Treatment Response in Human Multiple Myeloma

Lijie Xing, MD, Jiye Liu, PhD, Liang Lin, PhD, Shih-Feng Cho, MD PhD, Kenneth Wen, BS, Tengteng Yu, MD, Phillip Hsieh, Gang An, MD, Lugui Qiu, MD PhD, Nikhil Munshi, MD, Kenneth Anderson, MD, Yu-Tzu Tai, PhD

Blood (2018) 132 (Supplement 1): 407.

https://doi.org/10.1182/blood-2018-99-110317

Published: 2018

Journal Articles

Functional Role of Linc-RNAs in Multiple Myeloma: Linc-MIR17HG Affects Fatty Acid Biosynthesis Via transcriptional Regulation of ACC1 with Potential Therapeutic Implications

Eugenio Morelli, MD, Mariateresa Fulciniti, PhD, Mehmet Kemal Samur, PhD, Francesca Scionti, Annamaria Gulla, MD, Nicola Amodio, PhD, Giada Bianchi, MD, Tommaso Perini, MD, Cinzia Federico, PhD, Michael A Lopez, Maria Teresa Di Martino, Pierosandro Tagliaferri, Pierfrancesco Tassone, MD, Kenneth Anderson, MD, Nikhil Munshi, MD

Blood (2018) 132 (Supplement 1): 1925.

https://doi.org/10.1182/blood-2018-99-119572

Published: 2018

Journal Articles

Optimizing Mechanisms for Induction of Immunogenic Cell Death to Improve Patient Outcome in Multiple Myeloma

Annamaria Gulla, MD, Eugenio Morelli, MD, Teru Hideshima, MD PhD, Mehmet Kemal Samur, PhD, Giada Bianchi, MD, Mariateresa Fulciniti, PhD, Nikhil Munshi, MD, Kenneth C. Anderson, MD

Blood (2018) 132 (Supplement 1): 1932.

https://doi.org/10.1182/blood-2018-99-116951

Published: 2018

Journal Articles

Inhibitor of DNA Binding 2 (ID2) Plays a Key Tumor Suppressor Role in Promoting Oncogenic Transformation in Multiple Myeloma

Tommaso Perini, MD, Raphael Szalat, MD, Mehmet Kemal Samur, PhD, Mariateresa Fulciniti, PhD, Michael A Lopez, Matthew Lawlor, Christopher J. Ott, PhD, Na Li, MD, Yan Xu, MD, Kenneth Wen, BS, Nicola Amodio, PhD, Eugenio Morelli, MD, Kenneth Anderson, MD, Fabio Ciceri, MD, Nikhil Munshi, MD

Blood (2018) 132 (Supplement 1): 60.

https://doi.org/10.1182/blood-2018-99-118401

Published: 2018

Journal Articles

The Role of Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Multiple Myeloma: Immunomodulator Maintenance Post Autologous Stem Cell Transplant (ASCT) Predicts Better Outcome

Blood (2018) 132 (Supplement 1): 749.

https://doi.org/10.1182/blood-2018-99-113059

Published: 2018

Journal Articles

Interleukin-6 Adversely Impacts Genomic Stability Via Targeting Multiple Pathways in Multiple Myeloma

Chaitanya Yenumula, MD, Srikanth Talluri, PhD, Tommaso Perini, MD, Subodh Kumar, PhD, Jialan Shi, MD PhD, Rao Prabhala, PhD, Masood A. Shammas, PhD, Nikhil Munshi, MD

Blood (2018) 132 (Supplement 1): 4467.

https://doi.org/10.1182/blood-2018-99-119346

Published: 2018

Journal Articles

PDZ Binding Kinase (PBK) - a Novel Gene Driving Genomic Evolution in Multiple Myeloma

Subodh Kumar, PhD, Leutz Buon, Srikanth Talluri, PhD, Jialan Shi, MD PhD, Hervé Avet-Loiseau, MD PhD, Mehmet Kemal Samur, PhD, Masood A. Shammas, PhD, Nikhil Munshi, MD

Blood (2018) 132 (Supplement 1): 4474.

https://doi.org/10.1182/blood-2018-99-119186

Published: 2018

Journal Articles

Dysregulation of Splicing in Multiple Myeloma: The Splicing Factor SRSF1 Supports MM Cell Proliferation Via Splicing Control

Mariateresa Fulciniti, PhD, Michael A Lopez, Anil Aktas Samur, PhD, Eugenio Morelli, MD, Hervé Avet-Loiseau, MD PhD, Mehmet Kemal Samur, PhD, Nikhil Munshi, MD

Blood (2018) 132 (Supplement 1): 4500.

https://doi.org/10.1182/blood-2018-99-118845

Published: 2018

NARROW

The location of the t(4;14) translocation breakpoint within the NSD2 gene identifies a subset of patients with high-risk NDMM

Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed/refractory myeloma

Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA

Variable BCL2/BCL2L1 ratio in multiple myeloma with t(11;14)

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

Preclinical Validation Studies Support Causal Machine Learning Based Identification of Novel Drug Targets for High-Risk Multiple Myeloma

APRIL Is Significantly Elevated at All Stages of Multiple Myeloma (MM) and Interferes with Anti-Bcma Monoclonal Antibody-Mediated Cytolysis, Supporting the Clinical Evaluation of Bion-1301 As a Novel Therapeutic Approach in MM

A High-Risk Multiple Myeloma Group Identified By Integrative Multi-Omics Segmentation of Newly Diagnosed Patients

Deciphering the Chronology of Copy Number Alterations in Multiple Myeloma (MM): What Comes First?

Dysregulated Translational Control Is a Central Feature of MM Mediated By 14-3-3ε Interactome Promoting Multiple Myeloma Cell Growth and Viability

Activation of the Non-Canonical Estrogen Receptor Gper As a Novel Therapeutic Strategy Against WaldenstrÃ¶m Macroglobulinemia

Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

APOBEC3B Is Induced By Activation of DNA Repair Pathway and Modulates the Survival and Treatment Response in Human Multiple Myeloma

Functional Role of Linc-RNAs in Multiple Myeloma: Linc-MIR17HG Affects Fatty Acid Biosynthesis Via transcriptional Regulation of ACC1 with Potential Therapeutic Implications

Optimizing Mechanisms for Induction of Immunogenic Cell Death to Improve Patient Outcome in Multiple Myeloma

Inhibitor of DNA Binding 2 (ID2) Plays a Key Tumor Suppressor Role in Promoting Oncogenic Transformation in Multiple Myeloma

The Role of Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Multiple Myeloma: Immunomodulator Maintenance Post Autologous Stem Cell Transplant (ASCT) Predicts Better Outcome

Interleukin-6 Adversely Impacts Genomic Stability Via Targeting Multiple Pathways in Multiple Myeloma

PDZ Binding Kinase (PBK) - a Novel Gene Driving Genomic Evolution in Multiple Myeloma

Dysregulation of Splicing in Multiple Myeloma: The Splicing Factor SRSF1 Supports MM Cell Proliferation Via Splicing Control

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only